BMO Capital Markets reissued their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research note published on Wednesday. The firm currently has a $101.00 price target on the biotechnology company’s stock.

A number of other analysts have also recently commented on ONCE. Zacks Investment Research upgraded Spark Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, July 19th. ValuEngine upgraded Spark Therapeutics from a sell rating to a hold rating in a research report on Wednesday, July 19th. Chardan Capital restated a neutral rating on shares of Spark Therapeutics in a research report on Monday, July 24th. Jefferies Group LLC restated a buy rating and issued a $85.00 price target on shares of Spark Therapeutics in a research report on Monday, July 24th. Finally, Sanford C. Bernstein assumed coverage on Spark Therapeutics in a research report on Thursday, July 27th. They issued an outperform rating and a $87.00 price target for the company. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $90.36.

Spark Therapeutics (ONCE) traded up $3.72 during trading on Wednesday, reaching $73.08. The company had a trading volume of 495,412 shares, compared to its average volume of 398,888. Spark Therapeutics has a 12 month low of $47.03 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.07) EPS. equities analysts forecast that Spark Therapeutics will post -7.67 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Receives “Buy” Rating from BMO Capital Markets” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/spark-therapeutics-inc-once-receives-buy-rating-from-bmo-capital-markets.html.

In related news, insider Barge Joseph La sold 3,309 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $71.31, for a total transaction of $235,964.79. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at $580,891.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Faga sold 3,000 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.02, for a total value of $255,060.00. Following the sale, the insider now owns 3,000 shares of the company’s stock, valued at approximately $255,060. The disclosure for this sale can be found here. Insiders have sold 1,099,659 shares of company stock valued at $92,457,658 in the last quarter. 7.30% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its stake in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Spark Therapeutics during the second quarter valued at approximately $143,000. Teacher Retirement System of Texas bought a new position in Spark Therapeutics during the third quarter valued at approximately $225,000. Prudential Financial Inc. bought a new position in Spark Therapeutics during the third quarter valued at approximately $239,000. Finally, Commonwealth Equity Services Inc bought a new position in Spark Therapeutics during the third quarter valued at approximately $257,000. 77.94% of the stock is owned by institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.